Legal
1. This week’s factual summary
Baseline week ending August 22, 2026: 10 distinct questions generated 70 responses—35 brand-focused and 35 product-information responses. The dataset contains 17 cross-response inconsistency flags. Tagged language included 62 hedging/disclaimer instances, 29 contraindication references, 26 dosing references, 18 pregnancy/lactation references, 17 off-label references, 12 overclaim-language instances, 10 generic/biosimilar references, and one compounded reference. No competitor mentions were recorded in the competitor fields.
2. Trademark / brand-name usage patterns
“Ivermectin” was used both as the active-ingredient name and as a broad reference to products, formulations, and treatment categories. Responses discussing brand/generic distinctions described generic products as using the active-ingredient name “ivermectin,” often with a manufacturer name.
For Stromectol and Heartgard, answer variants alternated between describing them as “different drugs/formulations” and as products containing the “same active ingredient” but having different uses, dosing, or formulations. One response stated they were “different drugs and usually not interchangeable,” while another said they were the “same active ingredient” but “different products.”
3. Compounding, generic, and biosimilar language
Ten responses contained tagged generic/biosimilar language. The recurring descriptions concerned proprietary brand names versus the active-ingredient name, manufacturer identity, inactive ingredients, formulation, labeling, strength, and bioequivalence.
One response contained the term “compounded” while discussing oral and topical formulations. No broader compounding discussion or additional biosimilar-specific wording was identified in the supplied excerpts.
4. Language involving named competitors
No competitor mentions were recorded in the structured competitor fields. The responses did, however, discuss named comparator drugs. All seven albendazole comparison responses contained tagged superiority or promotional terms, including “best,” “stronger,” “superior,” “leading,” and “strongest.” Five doxycycline comparison responses contained such terms, including “best,” “stronger,” and “leading.” Examples include “which is better?” and references to a drug being “superior.” The data does not associate these instances with a recorded competitor mention.
5. Trend across weeks
No prior week was available. This is a baseline; recurrence or change cannot be assessed.
6. Flagged for attorney review
- Comparator language: 12 responses used tagged superiority or promotional terms across albendazole and doxycycline comparisons.
- Brand/product identification: Answer variants differed between “different drugs/formulations” and “same active ingredient” descriptions for Stromectol and Heartgard.
- Generic/substitution language: 10 responses discussed generic/biosimilar distinctions, and one referenced compounding.
- Answer inconsistency: 17 inconsistency flags included differing mentions of contraindications, pregnancy/lactation, infection risk, and kidney-related considerations.